For pharmaceutical and biotechnology companies, it is important to identify as many polymorphic forms of a small molecule therapeutic as possible, to mitigate threats from competitors and to create opportunities to optimise product performance.
Rapid Solid-State Screening Read More »
The Crystec mSAS® (modified supercritical anti-solvent) process offers distinct advantages in the development of high-performing inhaled products.
Particle Engineering to Optimise the Performance of Inhaled Therapeutics Read More »
mSAS® supercritical fluid technology marks a significant step forward in the stabilisation and processing of biomolecules.
Next-Generation Biomanufacturing Read More »
